J&J announces Phase 3 LIBREXIA-STROKE trial results evaluating milvexian, an oral factor XIa inhibitor, for secondary stroke prevention.

Roche announces positive Phase 3 ALINA trial results showing Alecensa (alectinib) significantly improves disease-free survival in resected ALK-positive NSCLC.

AbbVie announces Phase 2 trial results showing navitoclax plus ruxolitinib achieves hematologic responses in patients with polycythemia vera resistant or intolerant to hydroxyurea.

Merck presents five-year overall survival data from KEYNOTE-177 trial showing sustained benefit of Keytruda as first-line treatment for MSI-H/dMMR colorectal cancer.

Pfizer announces Phase 3 ALLEGRO trial results showing ritlecitinib significantly promotes hair regrowth in adults and adolescents with alopecia areata.

AstraZeneca announces Phase 3 trial results showing roxadustat effectively treats anemia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies.

Novartis announces Phase 3 APPEAR-C3G trial results showing iptacopan significantly reduces proteinuria and improves kidney function in C3 glomerulopathy.

Gilead Sciences presents overall survival data from ASCENT trial showing Trodelvy (sacituzumab govitecan) provides significant survival benefit in metastatic TNBC.

J&J announces Phase 3 LIBREXIA-STROKE trial results evaluating milvexian, an oral factor XIa inhibitor, for secondary stroke prevention.

Roche announces positive Phase 3 ALINA trial results showing Alecensa (alectinib) significantly improves disease-free survival in resected ALK-positive NSCLC.

AbbVie announces Phase 2 trial results showing navitoclax plus ruxolitinib achieves hematologic responses in patients with polycythemia vera resistant or intolerant to hydroxyurea.

Merck presents five-year overall survival data from KEYNOTE-177 trial showing sustained benefit of Keytruda as first-line treatment for MSI-H/dMMR colorectal cancer.

Pfizer announces Phase 3 ALLEGRO trial results showing ritlecitinib significantly promotes hair regrowth in adults and adolescents with alopecia areata.

AstraZeneca announces Phase 3 trial results showing roxadustat effectively treats anemia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies.

Novartis announces Phase 3 APPEAR-C3G trial results showing iptacopan significantly reduces proteinuria and improves kidney function in C3 glomerulopathy.

Gilead Sciences presents overall survival data from ASCENT trial showing Trodelvy (sacituzumab govitecan) provides significant survival benefit in metastatic TNBC.

Regeneron and Sanofi announce the FDA has approved Dupixent® (dupilumab) for adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamines, making Dupixent the first biologic approved for CSU in over a decade.

Bristol Myers Squibb announces FDA approval of Breyanzi® (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, expanding Breyanzi's indications to a fifth B-cell malignancy.

Pfizer announces that the Phase 3 MagnetisMM-9 trial evaluating elranatamab (Elrexfio®) plus standard-of-care in transplant-ineligible newly diagnosed multiple myeloma met its primary endpoint of progression-free survival, potentially expanding elranatamab's use to the frontline setting.

AstraZeneca announces FDA approval of Tagrisso® (osimertinib) for unresectable Stage III EGFR-mutated non-small cell lung cancer following concurrent platinum-based chemoradiation therapy, based on the landmark Phase 3 LAURA trial demonstrating an 84% reduction in disease progression risk.

GRAIL announces a favorable vote from the FDA's Molecular and Clinical Genetics Devices Panel for the Premarket Approval of the Galleri® multi-cancer early detection test (MCED), with the committee voting 7–2 that benefits outweigh risks for adults aged 50 and older.

Astellas Pharma announces the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel investigational KRAS G12D-targeted protein degrader, versus docetaxel in previously treated patients with advanced NSCLC — marking the second Phase 3 study of setidegrasib initiated within six months.

Novo Nordisk announces Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2.4 mg) as the first approved treatment in Singapore for adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2–F3), based on ESSENCE Phase 3 trial data showing 63% vs 34% steatohepatitis resolution.

Lantheus Holdings announces FDA final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for treatment of adult patients with somatostatin receptor-positive GEP-NETs.

Regeneron and Sanofi announce the FDA has approved Dupixent® (dupilumab) for adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamines, making Dupixent the first biologic approved for CSU in over a decade.

Bristol Myers Squibb announces FDA approval of Breyanzi® (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, expanding Breyanzi's indications to a fifth B-cell malignancy.

Pfizer announces that the Phase 3 MagnetisMM-9 trial evaluating elranatamab (Elrexfio®) plus standard-of-care in transplant-ineligible newly diagnosed multiple myeloma met its primary endpoint of progression-free survival, potentially expanding elranatamab's use to the frontline setting.

AstraZeneca announces FDA approval of Tagrisso® (osimertinib) for unresectable Stage III EGFR-mutated non-small cell lung cancer following concurrent platinum-based chemoradiation therapy, based on the landmark Phase 3 LAURA trial demonstrating an 84% reduction in disease progression risk.

GRAIL announces a favorable vote from the FDA's Molecular and Clinical Genetics Devices Panel for the Premarket Approval of the Galleri® multi-cancer early detection test (MCED), with the committee voting 7–2 that benefits outweigh risks for adults aged 50 and older.

Astellas Pharma announces the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel investigational KRAS G12D-targeted protein degrader, versus docetaxel in previously treated patients with advanced NSCLC — marking the second Phase 3 study of setidegrasib initiated within six months.

Novo Nordisk announces Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2.4 mg) as the first approved treatment in Singapore for adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2–F3), based on ESSENCE Phase 3 trial data showing 63% vs 34% steatohepatitis resolution.

Lantheus Holdings announces FDA final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA® for treatment of adult patients with somatostatin receptor-positive GEP-NETs.

New data from the SELECT trial confirms GLP-1 receptor agonists have cardioprotective effects beyond weight loss, potentially reshaping treatment guidelines for high-risk patients.

Researchers at the Broad Institute report a next-generation base editing platform that dramatically expands the scope of correctable hereditary conditions.

The designation accelerates development of a targeted therapy for non-small cell lung cancer patients with KRAS G12C mutations, affecting approximately 13% of cases.

New data from the SELECT trial confirms GLP-1 receptor agonists have cardioprotective effects beyond weight loss, potentially reshaping treatment guidelines for high-risk patients.

Researchers at the Broad Institute report a next-generation base editing platform that dramatically expands the scope of correctable hereditary conditions.

The designation accelerates development of a targeted therapy for non-small cell lung cancer patients with KRAS G12C mutations, affecting approximately 13% of cases.